Ancrod in acute stroke
Ancrod converts fibrinogen into soluble fibrin products, there by decreasing serum fibrinogen and reducing its use in thrombus formation.
In a trial of 500 patients, randomised to receive either Ancrod or placebo within 3 hours, 42% of patients given Ancrod had a total or near-total recovery compared to 34% in the placebo group.
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.